-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 8, Teyi Pharmaceuticals issued an announcement stating that the company had recently obtained the "Pyrazinamide Tablets" "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration.
Pyrazinamide tablets are anti-tuberculosis drugs that can be combined with other anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin and ethambutol) for the treatment of tuberculosis
Pyrazinamide tablets are among the national essential drugs, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Catalogue (2020 Edition)" Class A drugs, the first-line anti-tuberculosis drugs recommended by the World Health Organization (WHO), and the standard treatment for anti-tuberculosis treatment Basic drugs, according to the fourth edition of the "Guidelines for the Treatment of Tuberculosis" issued by the WHO Department of Tuberculosis Prevention and Treatment in 2010, the standard treatment plan for new patients is 2HRZE/4HR (H: Isoniazid; R: Rifampicin; Z: Pyrazinamide; E: Ethambutol)